178 related articles for article (PubMed ID: 38214111)
1. Prognostic biomarkers associated with immune checkpoint inhibitors in hepatocellular carcinoma.
Chen X; Kou L; Xie X; Su S; Li J; Li Y
Immunology; 2024 May; 172(1):21-45. PubMed ID: 38214111
[TBL] [Abstract][Full Text] [Related]
2. The Evolving Landscape of Checkpoint Inhibitor Combination Therapy in the Treatment of Advanced Hepatocellular Carcinoma.
Liu L; Qin S; Zhang Y
Target Oncol; 2021 Mar; 16(2):153-163. PubMed ID: 33528759
[TBL] [Abstract][Full Text] [Related]
3. Immune-Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: A Synopsis of Response Rates.
Shek D; Read SA; Nagrial A; Carlino MS; Gao B; George J; Ahlenstiel G
Oncologist; 2021 Jul; 26(7):e1216-e1225. PubMed ID: 33818870
[TBL] [Abstract][Full Text] [Related]
4. Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: A systematic review and meta-analysis.
Zheng J; Shao M; Yang W; Ren J; Chen X; Yang H
Int Immunopharmacol; 2022 Nov; 112():109244. PubMed ID: 36126410
[TBL] [Abstract][Full Text] [Related]
5. The Treatment Landscape of Advanced Hepatocellular Carcinoma.
Wong KM; King GG; Harris WP
Curr Oncol Rep; 2022 Jul; 24(7):917-927. PubMed ID: 35347594
[TBL] [Abstract][Full Text] [Related]
6. Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma.
Chen Y; Hu H; Yuan X; Fan X; Zhang C
Front Immunol; 2022; 13():896752. PubMed ID: 35757756
[TBL] [Abstract][Full Text] [Related]
7. First-line immune checkpoint inhibitor-based combinations in unresectable hepatocellular carcinoma: current management and future challenges.
Rizzo A; Ricci AD; Gadaleta-Caldarola G; Brandi G
Expert Rev Gastroenterol Hepatol; 2021 Nov; 15(11):1245-1251. PubMed ID: 34431725
[TBL] [Abstract][Full Text] [Related]
8. The evolution of immune checkpoint inhibitor combinations in advanced hepatocellular carcinoma - A systematic review.
Meyers BM; Knox JJ; Liu DM; McLeod D; Ramjeesingh R; Tam VC; Lim HJ
Cancer Treat Rev; 2023 Jul; 118():102584. PubMed ID: 37336142
[TBL] [Abstract][Full Text] [Related]
9. Biochemical predictors of response to immune checkpoint inhibitors in unresectable hepatocellular carcinoma.
Rizzo A; Brandi G
Cancer Treat Res Commun; 2021; 27():100328. PubMed ID: 33549983
[TBL] [Abstract][Full Text] [Related]
10. Beyond First-Line Immune Checkpoint Inhibitor Therapy in Patients With Hepatocellular Carcinoma.
Sharma R; Motedayen Aval L
Front Immunol; 2021; 12():652007. PubMed ID: 33790915
[TBL] [Abstract][Full Text] [Related]
11. Correlation Between Immune-Related Adverse Events and Prognosis in Hepatocellular Carcinoma Patients Treated With Immune Checkpoint Inhibitors.
Xu S; Lai R; Zhao Q; Zhao P; Zhao R; Guo Z
Front Immunol; 2021; 12():794099. PubMed ID: 34950153
[TBL] [Abstract][Full Text] [Related]
12. Hepatocellular carcinoma immune prognosis score predicts the clinical outcomes of hepatocellular carcinoma patients receiving immune checkpoint inhibitors.
Zhang R; Zhao H; Wang P; Guo Z; Liu C; Qu Z
BMC Cancer; 2023 Dec; 23(1):1181. PubMed ID: 38041022
[TBL] [Abstract][Full Text] [Related]
13. Current progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma.
Yin X; Wu T; Lan Y; Yang W
Biosci Rep; 2022 Feb; 42(2):. PubMed ID: 35075482
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety Associated With Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma: A Meta-analysis.
Jácome AA; Castro ACG; Vasconcelos JPS; Silva MHCR; Lessa MAO; Moraes ED; Andrade AC; Lima FMT; Farias JPF; Gil RA; Prolla G; Garicochea B
JAMA Netw Open; 2021 Dec; 4(12):e2136128. PubMed ID: 34870682
[TBL] [Abstract][Full Text] [Related]
15. Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma.
Ruff SM; Manne A; Cloyd JM; Dillhoff M; Ejaz A; Pawlik TM
Curr Oncol; 2023 Jun; 30(6):5863-5875. PubMed ID: 37366922
[TBL] [Abstract][Full Text] [Related]
16. The combination of circulating IgM and geriatric nutritional risk index predicts the prognostic of hepatocellular carcinoma patients who underwent immune checkpoint inhibitors.
Liu C; Zhao H; Wang P; Guo Z; Qu Z
Int Immunopharmacol; 2023 Oct; 123():110704. PubMed ID: 37506504
[TBL] [Abstract][Full Text] [Related]
17. Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours.
Celsa C; Cabibbo G; Fulgenzi CAM; Scheiner B; D'Alessio A; Manfredi GF; Nishida N; Ang C; Marron TU; Saeed A; Wietharn B; Pinter M; Cheon J; Huang YH; Lee PC; Phen S; Gampa A; Pillai A; Vivaldi C; Salani F; Masi G; Roehlen N; Thimme R; Vogel A; Schönlein M; von Felden J; Schulze K; Wege H; Galle PR; Kudo M; Rimassa L; Singal AG; El Tomb P; Ulahannan S; Parisi A; Chon HJ; Hsu WF; Stefanini B; Verzoni E; Giusti R; Veccia A; Catino A; Aprile G; Guglielmini PF; Di Napoli M; Ermacora P; Antonuzzo L; Rossi E; Verderame F; Zustovich F; Ficorella C; Di Pietro FR; Battelli N; Negrini G; Grossi F; Bordonaro R; Pipitone S; Banzi M; Ricciardi S; Laera L; Russo A; De Giorgi U; Cavanna L; Sorarù M; Montesarchio V; Bordi P; Brunetti L; Pinto C; Bersanelli M; Cammà C; Cortellini A; Pinato DJ
J Hepatol; 2024 Mar; 80(3):431-442. PubMed ID: 37972660
[TBL] [Abstract][Full Text] [Related]
18. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint inhibitor resistance in hepatocellular carcinoma.
Wang Z; Wang Y; Gao P; Ding J
Cancer Lett; 2023 Feb; 555():216038. PubMed ID: 36529238
[TBL] [Abstract][Full Text] [Related]
20. Advances in novel systemic therapies for advanced hepatocellular carcinoma.
Carloni R; Rizzo A; Cusmai A; Palloni A; Federico AD; Marco MD; Massafra R; Fanizzi A; Palmiotti G; Brandi G
Future Med Chem; 2022 Oct; 14(20):1455-1470. PubMed ID: 35997677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
